EC approves Raptor's Procysbi

The European Commission approved Procysbi cysteamine bitartrate from Raptor Pharmaceutical Corp. (NASDAQ:RPTP) to treat nephropathic cystinosis. Raptor plans to launch the delayed-release formulation of a degradation product of the amino acid cysteine in Europe in 1Q14. Raptor launched Procysbi in the U.S. in June with an annual average per patient cost of $250,000 (see BioCentury, May 20). ...